Compare NVAX & RXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVAX | RXRX |
|---|---|---|
| Founded | 1987 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | 1996 | 2021 |
| Metric | NVAX | RXRX |
|---|---|---|
| Price | $8.05 | $2.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $14.11 | $6.82 |
| AVG Volume (30 Days) | 5.8M | ★ 18.3M |
| Earning Date | 11-05-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 309.76 | 14.79 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,123,479,000.00 | $74,681,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 64.69 | 26.92 |
| 52 Week Low | $6.20 | $2.77 |
| 52 Week High | $13.39 | $5.24 |
| Indicator | NVAX | RXRX |
|---|---|---|
| Relative Strength Index (RSI) | 34.94 | 35.19 |
| Support Level | $7.48 | $2.90 |
| Resistance Level | $10.64 | $3.66 |
| Average True Range (ATR) | 0.71 | 0.31 |
| MACD | -0.23 | -0.09 |
| Stochastic Oscillator | 1.09 | 2.36 |
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.